Actively Recruiting

Phase Not Applicable
Age: 30Years +
FEMALE
NCT02945579

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Led by M.D. Anderson Cancer Center · Updated on 2026-03-09

120

Participants Needed

8

Research Sites

575 weeks

Total Duration

On this page

Sponsors

M

M.D. Anderson Cancer Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radiotherapy with no surgery. In ER positive/HER2 negative breast cancers, after endocrine therapy and ablative radiotherapy, when image-guided biopsy shows no residual cancer, patients then receive standard endocrine therapy with no surgery. For patients who have HER2 positive and triple negative breast cancers and standard surgery, after systemic therapy, breast radiotherapy is being eliminated when the pathology from surgery shows no residual cancer.

CONDITIONS

Official Title

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Who Can Participate

Age: 30Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female sex
  • Age 30 years or older (40 years or older for some cohorts)
  • Pathologically confirmed unicentric invasive breast cancer stage T1 or T2 (up to 5 cm), N0 or N1 (up to 4 abnormal lymph nodes), M0
  • HER2 positive (IHC 3+ or FISH amplified) or triple negative breast cancer (ER/PR < 10%, HER2 negative)
  • Patients desiring breast conserving therapy
  • For ER/PR positive HER2 negative cancer: clinical stage T1N0M0, non-lobular, no lymphovascular invasion
  • Oncotype score ≤ 25 if age ≥ 50; Oncotype 0-20 and tumor size ≤1.5 cm if age 40-49 for ER/PR positive patients
  • Agree to take anti-estrogen therapy if applicable
  • No evidence of residual invasive tumor or DCIS if undergoing surgery
  • No evidence of metastatic disease or isolated tumor cells in lymph nodes
  • Ability to undergo biopsy or surgery for tumor site when required
  • No history of prior radiation to the breast area requiring study treatment
  • For patients with prior non-breast cancer, all treatment must be completed and no evidence of disease
Not Eligible

You will not qualify if you...

  • Radiologic evidence of stage T3 or clinical stage T4 breast cancer (varies by cohort)
  • Evidence of distant metastases
  • Prior diagnosis of invasive or ductal carcinoma in situ in the same breast
  • Disease progression > 20% in the breast or new nodal metastases
  • Known pregnancy
  • Participation in a neoadjuvant systemic therapy protocol requiring surgical excision of breast or lymph nodes for certain cohorts

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

MD Anderson Cancer Center - Banner

Gilbert, Arizona, United States, 85234

Completed

2

Baptist MD Anderson Cancer Center

Jacksonville, Florida, United States, 32207

Actively Recruiting

3

Queen's Medical Center

Honolulu, Hawaii, United States, 96813

Completed

4

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

5

Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees

Voorhees Township, New Jersey, United States, 08103

Actively Recruiting

6

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, United States, 28203

Actively Recruiting

7

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, United States, 15232

Actively Recruiting

8

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

H

Henry Kuerer

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here